Immutep Ltd (ASX: IMM) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Immutep Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $421.21 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 748.15 million
Earnings per share -0.057
Dividend per share N/A
Year To Date Return 27.71%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Immutep Ltd (ASX: IMM)
Latest News

IMM ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Immutep Ltd

Immutep Ltd is a biotechnology company headquartered in Australia that focuses on personalised bio-therapeutic products for cancer.

IMM Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
20 Sep 2021 $0.54 $0.01 1.89% 2,439,045 $0.53 $0.55 $0.53
17 Sep 2021 $0.53 $-0.02 -3.64% 2,516,660 $0.54 $0.55 $0.53
16 Sep 2021 $0.55 $0.02 3.74% 800,623 $0.54 $0.56 $0.54
15 Sep 2021 $0.54 $-0.01 -1.85% 1,945,833 $0.53 $0.55 $0.52
14 Sep 2021 $0.54 $-0.02 -3.60% 907,898 $0.55 $0.55 $0.54
13 Sep 2021 $0.56 $-0.01 -1.79% 799,840 $0.57 $0.57 $0.55
10 Sep 2021 $0.56 $0.02 3.70% 1,628,472 $0.55 $0.57 $0.55
09 Sep 2021 $0.54 $-0.02 -3.54% 1,288,215 $0.57 $0.57 $0.54
08 Sep 2021 $0.57 $-0.02 -3.45% 997,919 $0.57 $0.58 $0.56
07 Sep 2021 $0.58 $-0.01 -1.69% 2,329,341 $0.60 $0.60 $0.57
06 Sep 2021 $0.59 $0.01 1.71% 853,337 $0.59 $0.60 $0.58
03 Sep 2021 $0.59 $0.02 3.54% 4,257,415 $0.58 $0.60 $0.58
02 Sep 2021 $0.57 $-0.01 -1.75% 2,015,361 $0.57 $0.58 $0.56
01 Sep 2021 $0.57 $0.04 7.55% 5,893,699 $0.56 $0.58 $0.55
31 Aug 2021 $0.53 $0.01 1.92% 1,961,001 $0.52 $0.53 $0.52
30 Aug 2021 $0.52 $0.00 0.00% 1,988,923 $0.52 $0.53 $0.51
27 Aug 2021 $0.52 $0.02 3.96% 3,172,247 $0.53 $0.54 $0.51
26 Aug 2021 $0.51 $0.03 6.32% 1,685,434 $0.49 $0.51 $0.48
25 Aug 2021 $0.48 $0.01 2.13% 765,248 $0.47 $0.49 $0.47
24 Aug 2021 $0.47 $0.03 6.74% 2,315,543 $0.45 $0.48 $0.45

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
24 Dec 2020 Russell Howard Transfer 500 $195,000
Off-market transfer. Assuming 500,000 Direct shares transferred to Indirect shares.
24 Dec 2020 Russell Howard Transfer 500 $195,000
Off-market transfer. Assuming 500,000 Direct shares transferred to Indirect shares.
24 Dec 2020 Russell Howard Buy 250 $97,500
Conversion of securities.
24 Dec 2020 Russell Howard Exercise 250 $97,500
Conversion of securities. 250,000 Director Performance Rights
06 Nov 2020 Grant Chamberlain Issued 1 $391,500
Issue of securities. 1,350,000 - Performance Rights
02 Oct 2020 Pete Meyers Exercise 273 $64,304
Conversion of securities. 1,500,000 - Performance Rights
02 Oct 2020 Pete Meyers Buy 273 $64,304
Conversion of securities.
02 Oct 2020 Marc Voigt Exercise 1 $282,000
Conversion of securities. 2,400,000 - Performance Rights
02 Oct 2020 Marc Voigt Buy 1 $282,000
Conversion of securities.
02 Oct 2020 Grant Chamberlain Buy 426 $100,263
Conversion of securities.
02 Oct 2020 Grant Chamberlain Exercise 426 $100,263
Conversion of securities.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Russell J Howard Non-Executive ChairmanNon-Executive Director May 2013
Dr Howard is an Australian scientist, executive manager and entrepreneur. He was a pioneer in molecular parasitology and commercialization of "DNA Shuffling". He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr. Howard worked at Schering-Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc. After its spin-out from GlaxoWellcome, as Maxygen's CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising US$ 260 million. Maxygen developed and partnered dozens of technology applications and products over 12 years of his tenure as CEO. After leaving Maxygen in 2008, he started the Cleantech company NovoNutrients Inc. (formerly Oakbio, Inc.) and remains involved in several innovative companies in the USA and Australia. He is currently Executive Chairman of NeuClone Pty Ltd.
Mr Pete A Meyers Non-Executive Deputy ChairmanNon-Executive Director Feb 2014
Mr Meyers is also the Chief Financial Officer of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX). Prior to joining Eagle Pharmaceuticals, Mr Meyers served in Chief Financial Officer roles at Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read & Co., Credit Suisse First Boston LLC and, most recently, as Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Mr. Meyers is the Chairman and President of The Thomas M. Brennan Memorial Foundation, Inc., and also serves on the Board of Directors of East End Hospice, Inc.
Mr Marc Voigt Chief Financial OfficerChief Executive OfficerExecutive Director May 2012
Mr Voigt has more than 20 years of experience in the financial and biotech industry. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net.IPO AG, a publicly-listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments. Marc then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specialising in healthcare. He also gained operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectfully, where he handled several successful licensing transactions and financing rounds. Since 2001, Marc has been a judge and coach in BPW, Germany's largest regional start-up initiative.
Mr Grant Chamberlain Non-Executive Director Aug 2017
Mr Chamberlain is a partner of One Ventures, one of Australia's leading venture capital firms. Prior to joining OneVentures in 2017 Mr Chamberlain was Head of Mergers & Acquisitions and Financial Sponsors Australia at Bank of America Merrill Lynch. Prior to joining Bank of America Merrill Lynch in 2013, Mr Chamberlain held senior positions at Nomura Australia and Deutsche Bank. He has over 20 years experience in investment banking and advised on many of the largest mergers and acquisitions transactions in Australia during that time. He began his career as a corporate lawyer at Freehill Hollingdale & Page.
Ms Deanne Miller Chief Operating OfficerCompany SecretaryGeneral Counsel
-
Ms Indira Naidu Joint Company Secretary Jan 2021
-
Deanne Miller Chief Operating OfficerCompany SecretaryGeneral Counsel
-
Frederic Triebel Chief Scientific Officer & Chief Medical Officer
-
Indira Naidu Joint Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Hsbc Custody Nominees (Australia) Limited 151,830,820 31.14%
National Nominees Limited 32,027,769 6.57%
Marc Voigt 7,591,695 1.56%
Citicorp Nominees Pty Limited 6,885,919 1.41%
Frederic Triebel 5,953,764 1.22%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 4,045,733 0.83%
J P Morgan Nominees Australia Pty Limited 3,980,049 0.82%
UBS Nominees Pty Ltd 3,615,960 0.74%
BNP Paribas Noms Pty Ltd <Drp> 3,375,624 0.69%
Deanne Miller 2,963,892 0.61%
Ms Lucy Turnbull 2,923,934 0.60%
Macenrock Pty Ltd <Macenrock S/F A/C> 2,800,670 0.57%
CS Third Nominees Pty Limited <Hsbc Cust Nom Au Ltd 13 A/C> 2,488,148 0.51%
Mr Matthew Caudle 1,985,375 0.41%
Mr Thomas Tscherepko 1,950,000 0.40%
M & Hc Pty Ltd <Caudle Investment A/C> 1,930,372 0.40%
HSBC Custody Nominees (Australia) Limited A/C 2 1,674,450 0.34%
Mr Ritchie Jay Campbell 1,602,000 0.33%
Peter Meyers 1,500,758 0.31%
HSBC Custody Nominees 1,483,246 0.30%

Profile

since

Note